GLUTAMATE DYNAMICS AND CLINICAL OUTCOME IN SCHIZOPHRENIA

精神分裂症的谷氨酸动力学和临床结果

• 批准号: 7954961
• 负责人: KELVIN O. LIM
• 金额: $ 1.28万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7954961
• 关键词: Accounting; Antipsychotic Agents; Brain; Brain imaging; Chemicals; Clinical; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Data; Defect; Diagnostic; Disease; Funding; Glutamates; Grant; Image; Institution; MRI Scans; Magnetic Resonance Imaging; Measures; Neurons; Neuropsychological Tests; Neuropsychology; Outcome; Participant; Patients; Pharmaceutical Preparations; Psychiatric Diagnosis; Research; Research Personnel; Research Project Grants; Resources; Schizophrenia; Source; Spectrum Analysis; Symptoms; Translating; United States National Institutes of Health; Visit; cerebral atrophy; follow-up; neuropsychological; outcome forecast; psychosocial; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our overall hypothesis is that early in schizophrenia there are changes in specific brain chemicals. These changes disrupt neuronal function in several distributed brain networks and accounts for the cortical atrophy, cognitive defects and poor psychosocial outcomes of the illness, despite the beneficial symptom reducing effects of antipsychotic medication. Related to the specific study of glutamate and its hypothesized impact on brain imaging and neuropsychological parameters is the hypothesis that imaging and neuropsychological measures can be useful in clarifying psychiatric diagnosis and prognosis. In translating this research project to the clinical arena, the data from brain imaging and neuropsychology will be analyzed to assess the utility of these measures to assist in diagnostic certainty. In addition, some studies have found that brain imaging measures are related to medication response. Therefore, imaging and neuropsychological testing will be correlated with symptomatic outcome at follow-up visits. We propose to study 15 minimally-treated, young patients with a schizophrenia spectrum disorder and 15 matched controls. At baseline, all participants will complete a diagnostic assessment, neuropsychological testing, and MRI scanning. The MRI scans will be repeated at 3, 6, and 12 months intervals.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 我们的总体假设是，在精神分裂症早期，特定的大脑化学物质发生了变化。尽管抗精神病药物可以减轻症状，但这些变化会破坏多个分布式大脑网络中的神经元功能，并导致皮质萎缩、认知缺陷和不良的心理社会结果。 与谷氨酸的具体研究及其对脑成像和神经心理学参数的假设影响相关的是成像和神经心理学测量可有助于澄清精神病学诊断和预后的假设。在将该研究项目转化为临床领域时，将分析来自脑成像和神经心理学的数据，以评估这些措施在协助诊断确定性方面的效用。此外，一些研究发现大脑成像测量与药物反应有关。因此，影像学和神经心理学测试将与随访时的症状结果相关。 我们计划研究 15 名接受过最低限度治疗的年轻精神分裂症谱系障碍患者和 15 名匹配的对照者。在基线时，所有参与者都将完成诊断评估、神经心理学测试和 MRI 扫描。 MRI 扫描将每隔 3、6 和 12 个月重复一次。